カンパス-1H(Campath-1H)による多発性硬化症(MS)治療 - Alcafloy Management Gesell Shaft Mitt Beschlenktel Haftung Und Companie Commandito Gesell Shaft

Title:

カンパス-1H(Campath-1H)による多発性硬化症(MS)治療

Document Type and Number:

Japanese Patent JP2010503631

Kind Code:

A

Abstract:

A method for treatment of multiple sclerosis (MS) with Campath-1H with significant efficacy and a favourable safety profile is described, which offers an acceptable benefit/risk ratio. Especially described is the use of Campath-1H (alemtuzumab) for the production of a medicament for the treatment of multiple sclerosis (MS), comprising a first treatment cycle followed by at least one further treatment cycle of Campath-1H (alemtuzumab), in which each treatment cycle comprises 1-5 daily doses which are applied on consecutive days, wherein the daily dose is >0 and ¤ 12 mg, and wherein each treatment cycle is separated from the next cycle by at least 1 - 24 months. Also described are treatment regimens comprising the administration of less than 12 mg/day of Campath-1H for a period of 1-5 consecutive days.

Inventors:

Andreas, Sachse
Margoline, David Harris

Application Number:

JP2009527751A

Publication Date:

February 04, 2010

Filing Date:

September 11, 2007

Export Citation:

Click for automatic bibliography generation Help

Assignee:

Alcafloy Management Gesell Shaft Mitt Beschlenktel Haftung Und Companie Commandito Gesell Shaft
Genzyme Corporation

International Classes:

A61K39/395; A61P25/00

Domestic Patent References:

JPH07504888A

1995-06-01

Other References:

JPN5009012800; ＣＯＬＥＳ，ＡＪ．　ｅｔ　ａｌ: ＪＯＵＲＮＡＬ　ＯＦ　ＮＥＵＲＯＬＯＧＹＶｏｌ．２５３, 200601, ｐ．９８-１０８
JPN6012048233; ＣＯＬＥＳ，ＡＪ．　ｅｔ　ａｌ: ＣＬＩＮＩＣＡＬ　ＮＥＵＲＯＬＯＧＹ　ＡＮＤ　ＮＥＵＲＯＳＵＲＧＥＲＹＶｏｌ．１０６, 2004, ｐ．２７０-２７４
JPN7013002904; ＣＡＭＭＳ２２３試験の中間結果，　Ｇｅｎｚｙｍｅ　Ｃｏｒｐｏｒａｔｉｏｎ　ａｎｄ　Ｓｃｈｅｒｉｎｇ　ＡＧ，　２００５年９月１６日付けのプレスリリース

Attorney, Agent or Firm:

Atsushi Aoki
Takashi Ishida
Fukumoto product
Tetsuji Koga
Yoichi Watanabe
Kazuhiro Nakamura
Masaru Nakajima

Previous Patent: ＨＭＧＢ１のＢｏｘ−ＡおよびＨＭＧＢ１のＢｏｘ−Ａ変異体のポリマー�...

Next Patent: 経口改良放出製剤